Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Phase 4 Terminated 20 enrolled Baxter Healthcare Corporation Halozyme Therapeutics · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.

Timeline

Start: 2010-05
Primary completion: 2010-05
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rHuPH20	Protein / enzyme biologic	150 iu	Subcutaneous
Background	Lactated Ringer's solution	Unknown	1000 ml	Subcutaneous

Indications

No indication recorded.